Abbvie Inc.

Abbott Laboratories Corporation

Abb Vie Deutschland Gmbh & Co. Kg

Abbvic Inc.

Abbvie Ireland Unlimited Company

Walid M Awni

Sandeep Dutta

Barry M Bernstein

Sven Mensing

Thomas J Podsadecki

Rajeev M Menon

Cheri E Klein

Daniel E Cohen

Scott C Brun

Emily O Dumas

Amit Khatri

Wei Liu

Tianli Wang

Andrew L Campbell

Chih-Wei Lin

Elliot Keith Chartash

Susan K Paulson

William T Barchuk

Mario D Saltarelli

Joaquin Mario Valdes

Martin M Okun

Martin Kaul

William G Glass

Kenneth B Gordon

Tushar S Garimella

Walid M Abi-Saab

Earle E Bain

Peter Noertersheuser

Parvez M Mulani

Tom C Harris

Yihua Gu

Yanjun Bao

The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

Methods for treating HCV

Method for treating HCV

The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.

The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).

The invention provides methods of treating psoriasis in a subject by administering to a subject an antibody capable of binding to the p40 subunit of IL-12 and/or IL-23.

Methods for treating psoriasis using antibodies that bind to the P40 subunit of IL-12 and/or IL-23

3-(5,6-Dichloro-pyridin-3-yl)-1S,5S-3,6-diazabicyclo[3.2.0]heptane and salts thereof are effective nicotinic receptor agonist compounds that demonstrated pharmacological effect for symptoms associated with attention-deficit/hyperactivity disorder.

Treatment of attention-deficit/hyperactivity disorder

Growing community of inventors

Green Oaks, IL, United States of America

Walid M Awni